Quest Diagnostics (NYSE:DGX – Get Free Report) is projected to post its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect Quest Diagnostics to post earnings of $2.81 per share and revenue of $2.9727 billion for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. The company had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.94 earnings per share. On average, analysts expect Quest Diagnostics to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
Quest Diagnostics Stock Performance
DGX opened at $206.59 on Wednesday. The business has a fifty day simple moving average of $201.19 and a 200 day simple moving average of $196.73. The company has a market capitalization of $22.87 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 2.47 and a beta of 0.58. Quest Diagnostics has a 1 year low of $165.78 and a 1 year high of $219.20. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08.
Quest Diagnostics Dividend Announcement
Insiders Place Their Bets
In other news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.
Institutional Investors Weigh In On Quest Diagnostics
Large investors have recently bought and sold shares of the company. State Street Corp raised its position in shares of Quest Diagnostics by 3.0% in the 4th quarter. State Street Corp now owns 5,382,547 shares of the medical research company’s stock valued at $934,033,000 after buying an additional 158,617 shares in the last quarter. Boston Partners lifted its holdings in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the period. Morgan Stanley boosted its position in shares of Quest Diagnostics by 17.8% during the 4th quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock worth $467,415,000 after acquiring an additional 406,658 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Quest Diagnostics by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,931,548 shares of the medical research company’s stock worth $335,204,000 after acquiring an additional 24,038 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Quest Diagnostics by 1.8% in the third quarter. Invesco Ltd. now owns 1,688,769 shares of the medical research company’s stock valued at $321,846,000 after acquiring an additional 30,418 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
DGX has been the subject of a number of recent research reports. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. Robert W. Baird raised their price target on shares of Quest Diagnostics from $232.00 to $236.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. UBS Group lifted their price objective on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 22nd. Evercore set a $225.00 price objective on shares of Quest Diagnostics in a report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus price target of $217.17.
Check Out Our Latest Research Report on Quest Diagnostics
Quest Diagnostics Company Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Featured Articles
- Five stocks we like better than Quest Diagnostics
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
